Resources from the same session
176O - Final overall survival (OS) results from the phase III PAOLA-1/ENGOT-ov25 trial evaluating maintenance olaparib (ola) plus bevacizumab (bev) in patients (pts) with newly diagnosed advanced ovarian cancer (AOC)
Presenter: Shoji Nagao
Session: Proffered Paper session: Gynaecological tumours
Resources:
Abstract
Slides
Webcast
177O - Lenvatinib plus pembrolizumab versus treatment of physician’s choice in patients with previously treated advanced endometrial cancer: Study 309/KEYNOTE-775 Asian subgroup
Presenter: Kan Yonemori
Session: Proffered Paper session: Gynaecological tumours
Resources:
Abstract
Slides
Webcast
178O - Rucaparib maintenance treatment in patients (pts) with newly diagnosed ovarian cancer (OC): Defining benefit according to disease risk subgroups within the phase III ATHENA–MONO study
Presenter: Keiichi Fujiwara
Session: Proffered Paper session: Gynaecological tumours
Resources:
Abstract
Slides
Webcast
Q&A and discussion
Presenter: Michael Friedlander
Session: Proffered Paper session: Gynaecological tumours
Resources:
Slides
Webcast
179O - A phase II, open-label, single-arm study of QL1604 plus paclitaxel-cisplatin/carboplatin as first-line treatment in patients with recurrent or metastatic cervical cancer
Presenter: Jihong Liu
Session: Proffered Paper session: Gynaecological tumours
Resources:
Abstract
Slides
Webcast
180O - Efficacy and safety of zimberelimab (GLS-010) monotherapy in patients with recurrent or metastatic cervical cancer: A multicenter, open-label, single-arm, phase II study
Presenter: Xiaohua Wu
Session: Proffered Paper session: Gynaecological tumours
Resources:
Abstract
Slides
Webcast
Invited Discussant 179O and 180O
Presenter: Paul Cohen
Session: Proffered Paper session: Gynaecological tumours
Resources:
Slides
Webcast